surabgene lomparvovec

AXP000257.1 · Viral vector gene therapy

Platform
AAV8 vector (NAV)
Originator
REGENXBIO
Sponsor
AbbVie

Names

NameTypeSource
surabgene lomparvovecpreferred namecurator
ABBV-RGX-314codectgov
sura-vecsynonymctgov
RGX-314former codectgov

Virus

Role
In vivo gene transfer
Family
Parvoviridae
Virus
adeno-associated virus 8
Strain
AAV8
Replication
non replicating
Modifications
NAV vector encoding an anti-VEGF antibody fragment
Transgenes
anti-VEGF Fab (ranibizumab-like)
Route
subretinal, suprachoroidal
Source
evidence

Approvals

No regulatory approval recorded.

Clinical trials (10)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT07592273Surabgene Lomparvovec Administered in the Suprachoroidal Space in Adult Participants With Diabetic Retinopathy Without Center-Involved Diabetic Macular EdemaRecruitingPhase 2/32026-06-012028-06576Diabetic Retinopathy
NCT07007065Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)RecruitingPhase 32025-11-052033-03561Neovascular Age-related Macular Degeneration
NCT06942520Phase 2 Trial of RGX-314 in Adults With Center Involved - Diabetic Macular Edema (CI - DME)RecruitingPhase 22025-03-182027-1218Diabetic Macular Edema
NCT05407636Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMDActive not recruitingPhase 32022-01-132026-10735AMD; CNV; Wet Age-related Macular Degeneration; WetAMD; nAMD; wAMD
NCT04832724RGX-314 Gene Therapy Pharmacodynamic Study for Neovascular Age-related Macular Degeneration (nAMD)CompletedPhase 22021-02-222023-10-0260Neovascular Age-related Macular Degeneration; Wet Age-related Macular Degeneration; Wet Macular Degeneration
NCT04704921Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMDActive not recruitingPhase 2/32020-12-292026-12671AMD; CNV; Choroidal Neovascularization; Neovascular AMD; Neovascular Age-related Macular Degeneration; Wet AMD; Wet Age-related Macular Degeneration; nAMD; wAMD
NCT04567550RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Diabetic Retinopathy (DR) With and Without Center Involved-Diabetic Macular Edema (CI-DME)Active not recruitingPhase 22020-11-202026-06-18139Center-Involved Diabetic Macular Edema (CI-DME); Diabetic Retinopathy (DR)
NCT04514653RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD)Active not recruitingPhase 22020-08-252026-08146Neovascular Age-Related Macular Degeneration (nAMD)
NCT03999801Long-term Follow-Up Study of RGX-314 and Fellow Eye SubstudyEnrolling by invitationPhase 22019-05-312028-12865Neovascular Age-related Macular Degeneration; Wet Macular Degeneration
NCT03066258Safety and Tolerability of RGX-314 (Investigational Product) Gene Therapy for Neovascular AMD TrialCompletedPhase 1/22017-03-292019-11-2442Neovascular Age-related Macular Degeneration; Wet Age-related Macular Degeneration
Unconfirmed matches (2)

Trials that mention one of the names in a weaker way (a code only in the title, a short or ambiguous name). Not counted above.

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditionsMatched by
NCT05296447Long-Term Follow-Up Study of RGX-314 Administered in the Suprachoroidal Space for Participants With and Without Diabetic RetinopathyActive not recruitingPhase 22022-04-042031-06103Diabetic Retinopathy, DRname in title: RGX-314
NCT05210803Long-Term Follow-Up Study of RGX-314 Administered in the Suprachoroidal Space for Participants With nAMDEnrolling by invitationPhase 22021-12-202031-07116Neovascular Age-Related Macular Degeneration (nAMD)name in title: RGX-314

Recent changes

No changes recorded in its trials yet.

Clinical papers

PubMedTitleJournalYearLinked by
PMID 38554726Gene therapy for neovascular age-related macular degeneration by subretinal delivery of RGX-314: a phase 1/2a dose-escalation study.Lancet (London, England)2024cited by trial NCT03066258

Other papers

Preclinical studies, reviews and other papers that name it.

PubMedTitleJournalYearLinked by
PMID 41490387Emerging solutions for neovascular age-related macular degeneration.Current opinion in ophthalmology2026name in abstract: ABBV-RGX-314
PMID 41688763AAV-based gene therapies for neovascular AMD.Gene therapy2026name in abstract: RGX-314
PMID 39379521Exploring new horizons in neovascular age-related macular degeneration: novel mechanisms of action and future therapeutic avenues.Eye (London, England)2025name in abstract: RGX-314
PMID 40293479Gene therapy in neovascular age related macular degeneration: an update.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie2025name in abstract: RGX-314
PMID 40319468Beyond the injection: delivery systems reshaping retinal disease management.Expert opinion on pharmacotherapy2025name in abstract: ABBV-RGX-314
PMID 40364236Gene Therapy in Diabetic Retinopathy and Diabetic Macular Edema: An Update.Journal of clinical medicine2025name in abstract: ABBV-RGX-314
PMID 40601510Gene Therapy in Age-related Macular Degeneration.International ophthalmology clinics2025name in abstract: RGX-314
PMID 41042032Computational Fluid Dynamics Modeling of Intravitreal Ranibizumab Bolus Versus Subretinal ABBV-RGX-314 Transgene Product in Human Eyes.Translational vision science & technology2025name in title: ABBV-RGX-314
PMID 38330506Advancements in the treatment of age-related macular degeneration: a comprehensive review.Postgraduate medical journal2024name in abstract: RGX-314
PMID 38927656Gene Therapy for Non-Hereditary Retinal Disease: Age-Related Macular Degeneration, Diabetic Retinopathy, and Beyond.Genes2024name in abstract: ABBV-RGX-314
PMID 35017696Review of gene therapies for age-related macular degeneration.Eye (London, England)2022name in abstract: RGX-314
PMID 35962560Investigational drugs in clinical trials for macular degeneration.Expert opinion on investigational drugs2022name in abstract: RGX-314
PMID 33671815Suprachoroidal Delivery of Small Molecules, Nanoparticles, Gene and Cell Therapies for Ocular Diseases.Pharmaceutics2021name in abstract: RGX-314
PMID 34188445Vascular Endothelial Growth Factor Antagonists: Promising Players in the Treatment of Neovascular Age-Related Macular Degeneration.Drug design, development and therapy2021name in abstract: RGX-314
PMID 32511123Emerging Therapies in Neovascular Age-Related Macular Degeneration in 2020.Asia-Pacific journal of ophthalmology (Philadelphia, Pa.)2020name in abstract: RGX-314
PMID 31298960Innovative therapies for neovascular age-related macular degeneration.Expert opinion on pharmacotherapy2019name in abstract: RGX-314
PMID 31408444AAV8-vectored suprachoroidal gene transfer produces widespread ocular transgene expression.The Journal of clinical investigation2019name in abstract: RGX-314

Notes

NAV AAV8 vector encoding a ranibizumab-like anti-VEGF antibody fragment for neovascular age-related macular degeneration, given subretinally in the pivotal trials (ATMOSPHERE NCT04704921, NCT05407636) and suprachoroidally in others. `targets` is empty: the transgene is an antibody fragment, not a human gene, so no HGNC symbol applies.

How to cite

surabgene lomparvovec (AXP000257.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000257.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.